Premium
Adiponectin downregulates galectin‐3 whose cellular form is elevated whereas its soluble form is reduced in type 2 diabetic monocytes
Author(s) -
Weber Markus,
Sporrer Daniela,
Weigert Johanna,
Wanninger Josef,
Neumeier Markus,
Wurm Sylvia,
Stögbauer Fabian,
Kopp Andrea,
Bala Margarita,
Schäffler Andreas,
Buechler Christa
Publication year - 2009
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2009.10.008
Subject(s) - adiponectin , monocyte , galectin 3 , galectin , endocrinology , medicine , chemistry , galectin 1 , macrophage , overweight , obesity , immunology , biochemistry , insulin resistance , in vitro
Galectin‐3 plays a role in atherosclerotic diseases, and the effect of adiponectin that protects from atherosclerotic diseases on monocytic galectin‐3 was analysed. Adiponectin reduced galectin‐3 mRNA, its cellular and soluble form, and this effect was impaired in T2D cells. Cellular galectin‐3 was higher in monocytes of overweight than normal‐weight donors and was highest in T2D cells. Cellular galectin‐3 positively correlated with the BMI of the donors and negatively with soluble monocyte galectin‐3. Circulating levels of total adiponectin did not correlate with cellular or soluble galectin‐3 indicating that additional factors contribute to higher cellular monocytic galectin‐3 in obesity and T2D.